Tirzepatide is used in regulated prescription medicines for type 2 diabetes and weight management. Human evidence for those medicines does not verify a product labelled TR10.
TR10 is not a regulated brand name or proof of tirzepatide identity.
TR10 may be presented as tirzepatide, but a shorthand label does not verify that identity.
Reported benefits, not product promises
Personal stories are anecdotal. They cannot show whether a product caused a change, how often it happens or what the risks are.
Unlike most entries here, these outcomes have been shown in large trials of named, quality-controlled tirzepatide medicines. That evidence does not verify a TR10-labelled product or make it suitable for an individual.
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in named, quality-controlled prescription medicines. TR10 is a shorthand label, not proof that a product contains tirzepatide or matches the medicine studied.
This phase 3 randomised trial enrolled 2,539 adults with obesity, or overweight plus a weight-related condition, and excluded diabetes. At 72 weeks, average body-weight change ranged from minus 15.0% to minus 20.9% across tirzepatide groups, compared with minus 3.1% with placebo. These results belong to the trial medicine and its clinical setting.
Jastreboff et al., New England Journal of Medicine (2022): Tirzepatide once weekly for the treatment of obesityIn 1,879 adults with type 2 diabetes taking metformin, the 40-week phase 3 trial reported average reductions in HbA1c, a measure of average blood sugar, of 2.01 to 2.30 percentage points across tirzepatide groups, versus 1.86 points with the 1 mg semaglutide comparator used in this trial. Nausea and diarrhoea were among the most common reported adverse events. This is clinical evidence for the specified trial treatment, not TR10.
Frías et al., New England Journal of Medicine (2021): Tirzepatide versus semaglutide once weekly in patients with type 2 diabetesThese trials give us useful evidence for the medicine and groups of people they studied. A code alone cannot establish ingredient identity, strength, safety controls or medical suitability.
Research topics are not a promise of benefits.
Mounjaro, containing tirzepatide, has Medsafe consent and prescription classification in New Zealand.
A product called TR10 cannot be assumed to be Mounjaro, contain tirzepatide or have the same quality controls.
This is not a complete list of risks or a personal safety assessment.
Keep its packaging and ingredient information. Check the formulation, instructions and supplies together. An unidentified product cannot be made safe by an online dose calculation.
Before mixing: checks & suppliesOnly the regulated prescription product has the cited Medsafe status. Seek clinical advice for a regulated medicine.
“Research purposes only” is not a legal exemption or a safety guarantee. This guide is for research and educational purposes only and does not recommend taking this substance.
Read Medsafe’s warningThe things you might be wondering.
No. Mounjaro is a named Medsafe-consented prescription medicine; TR10 does not prove equivalence.
Regulated tirzepatide products are indicated for type 2 diabetes and specified chronic weight-management use.
There is no universal dose. Tirzepatide treatment requires a clinician and a confirmed regulated product.
Two conversations on appetite, weight-loss medicines and the wider peptide research. Pick a thumbnail to watch here.
Huberman Lab · 17 June 2024
Why do we feel hungry, and what makes us feel full? Neuroscientist Dr Zachary Knight explains how the brain controls appetite, cravings and food choices. He and Andrew Huberman also explore semaglutide, tirzepatide and related medicines, including how they work and their side effects. A useful companion to the tirzepatide research guide.
Play loads the YouTube player. Podcast discussion is context, not medical advice.
Huberman Lab · 1 June 2026
Why are peptides getting so much attention? Dr Abud Bakri joins Andrew Huberman to discuss BPC-157, GHK-Cu, melanotan and GLP-1 medicines. They explore what is being studied, why product sourcing matters and where animal findings still need to be tested in humans.
Play loads the YouTube player. Podcast discussion is context, not medical advice.